The message from this post is that you need to engage with your own monitoring; don't be shy to ask about your blood results.
Muñoz et al. Liver injury associated with dimethyl fumarate in multiple sclerosis patients. Mult Scler. 2017 Jan 1:1352458516688351
BACKGROUND: In pre-approval trials, there was an increased incidence of mild, transient elevations of liver aminotransferases in study subjects treated with dimethyl fumarate (DMF).
OBJECTIVE/METHODS: To evaluate post-marketing cases of drug-induced liver injury associated with DMF.
RESULTS: We identified 14 post-marketing cases of clinically significant liver injury. Findings included newly elevated serum liver aminotransferase and bilirubin levels that developed as early as a few days after the first dose of DMF. The pattern of liver injury was primarily hepatocellular. No cases resulted in liver failure.
CONCLUSION: Health professionals should be alerted to possible serious liver injury in patients receiving DMF.